CoChat

Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study

Kang, Won Ki, Park, Chaehwa, Yoon, Hyunah Lee, Kim, Won Seog, Yoon, Sung-Soo, Lee, Mark H., Park, Keunchil, Kim, Kihyun, Jeong, Hyun Sik, Kim, Jeong-A, Nam, Seok-Jin, Yang, Jung-Hyun, Son, Young-Ik, Baek, Chung-Hwan, Han, Jungho, Ree, Howe J., Lee, Eil Soo, Kim, Sun Hee, Kim, Dae-Won, Ahn, Yong Chan, Huh, Seung Jae, Choe, Yeon Hyeon, Lee, Je-Ho, Park, Mary H., Kong, Gyoung-Sun, Park, Eun-Young, Kang, Yoon-Koo, Bang, Yung-Jue, Paik, Nam-Sun, Lee, Soon Nam, Kim, Seon-Hee, Kim, Sunyoung, Robbins, Paul D., Tahara, Hideaki, Lotze, Michael T., Park, Chan H. · 2001 · Human Gene Therapy
Cited by 135

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

A phase I dose-escalation clinical trial of peritumoral injections of interleukin 12 (IL-12)-transduced autologous fibroblasts was performed in patients with disseminated cancer for whom effective treatment does not exist. The goals of this study were to assess the safety and toxicities as well as the efficacy, and ancillarily the immunomodulatory effects, of peritumoral IL-12 gene transfer. Primary dermal fibroblasts cultured from the patients were transduced with retroviral vector carrying human IL-12 genes (p35 and p40) as well as the neomycin phosphotransferase gene (TFG-hIL-12-Neo). Patients received four injections at intervals of 7 days. Nine patients were enrolled in this dose-escalation study, with secreted IL-12 doses ranging from 300 ng/24 hr for the first three patients to 1000, 3000, and 5000 ng/24 hr for two patients in each subsequent dosage level. Although a definite statement cannot be made, there appears to be perturbation of systemic immunity. Also, the locoregional effects mediated by tumor necrosis factor alpha (TNF-alpha) and CD8+ T cells were observed with tumor regression. Treatment-related adverse events were limited to mild to moderate pain at the injection site; clinically significant toxicities were not encountered. Transient but clear reductions of tumor sizes were observed at the injected sites in four of nine cases, and at noninjected distant sites in one melanoma patient. Hemorrhagic necrosis of tumors was observed in two melanoma patients. These data indicate that gene therapy by peritumoral injection of IL-12-producing autologous fibroblasts is feasible, and promising in patients with advanced cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/104303401300057388

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 135

Metadata

Authors
Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S.-S., Lee, M. H., Park, K., Kim, K., Jeong, H. S., Kim, J.-A., Nam, S.-J., Yang, J.-H., Son, Y.-I., Baek, C.-H., Han, J., Ree, H. J., Lee, E. S., Kim, S. H., Kim, D.-W., Ahn, Y. C., Huh, S. J., Choe, Y. H., Lee, J.-H., Park, M. H., Kong, G.-S., Park, E.-Y., Kang, Y.-K., Bang, Y.-J., Paik, N.-S., Lee, S. N., Kim, S.-H., Kim, S., Robbins, P. D., Tahara, H., Lotze, M. T., & Park, C. H.
Venue
Human Gene Therapy
Published
2001-04-10
Volume
12
Issue
6
Pages
671-684
ISSN
  • 1043-0342 (ISSN-L)
  • 1557-7422
OpenAlex
W2175689371
Cited by
135
References
1
FWCI
4.42
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study. https://app.cochat.ai/papers/10.1089/104303401300057388
The paper
Kang, W. K., Park, C., Yoon, H. L., Kim, W. S., Yoon, S.-S., Lee, M. H., Park, K., Kim, K., Jeong, H. S., Kim, J.-A., Nam, S.-J., Yang, J.-H., Son, Y.-I., Baek, C.-H., Han, J., Ree, H. J., Lee, E. S., Kim, S. H., Kim, D.-W., . . . Park, C. H. (2001). Interleukin 12 Gene Therapy of Cancer by Peritumoral Injection of Transduced Autologous Fibroblasts: Outcome of a Phase I Study. Human Gene Therapy. https://doi.org/10.1089/104303401300057388

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.